2022.03.29
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021
I-Mab today announced financial results for the 12 months ended December 31, 2021, and provided key business updates.
We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
2022.03.29
I-Mab today announced financial results for the 12 months ended December 31, 2021, and provided key business updates.
2022.03.18
I-Mab today announced that the Company will report financial results for the full year ended December 31, 2021 before the market opens on Tuesday, March 29, 2022.
2022.03.15
I-Mab today provides updates on the recent development relating to the HFCAA and its implementation.
2022.03.09
I-Mab today announced that two poster presentations featuring translational research data of enoblituzumab and preclinical data of TJ-C64B will be presented at AACR 2022.
2022.03.03
I-Mab today announced that the U.S. FDA has granted Orphan Drug Designation for TJ-CD4B for the treatment of gastric cancer including cancer of gastroesophageal junction.
2022.01.28
I-Mab announced the signing of a partnership agreement with the Hangzhou Qiantang New Area in China to manufacture its innovative drugs locally and accelerate its transition to commercialization.
2022.01.18
I-Mab today announced that the first patient has been dosed in its China phase 2 trial of lemzoparlimab in combination with the PD-1 antibody toripalimab in patients with advanced solid tumors.
2022.01.14
The senior management team of the Company have executed the share purchase plan with the open market purchase of 70,000 of the Company’s ADS in an aggregate amount of over US$2.6 million as of 14 Jan, 2022.
2022.01.12
I-Mab today announced that the first patient had been dosed in its China phase 2 study of efineptakin alfa in combination with pembrolizumab in patients with advanced solid tumors.
2022.01.06
I-Mab today announced that the senior management team have informed the Company of their intention to use their personal funds to purchase the Company's American depositary shares on the open market for an aggregate amount of minimum US$3 million and up to US$20 million no later than February 28, 20...